EVOK vs. KPTI, KALA, STTK, PEPG, ELYM, XLO, RANI, LTRN, AKTX, and LVTX
Should you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Karyopharm Therapeutics (KPTI), KALA BIO (KALA), Shattuck Labs (STTK), PepGen (PEPG), Eliem Therapeutics (ELYM), Xilio Therapeutics (XLO), Rani Therapeutics (RANI), Lantern Pharma (LTRN), Akari Therapeutics (AKTX), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical products" industry.
Evoke Pharma vs. Its Competitors
Evoke Pharma (NASDAQ:EVOK) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.
Evoke Pharma has higher earnings, but lower revenue than Karyopharm Therapeutics. Evoke Pharma is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Evoke Pharma has a net margin of -43.80% compared to Karyopharm Therapeutics' net margin of -43.99%. Karyopharm Therapeutics' return on equity of 0.00% beat Evoke Pharma's return on equity.
66.4% of Karyopharm Therapeutics shares are held by institutional investors. 6.1% of Evoke Pharma shares are held by company insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Karyopharm Therapeutics has a consensus target price of $37.40, suggesting a potential upside of 782.08%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Evoke Pharma.
In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Evoke Pharma. MarketBeat recorded 6 mentions for Karyopharm Therapeutics and 5 mentions for Evoke Pharma. Evoke Pharma's average media sentiment score of 0.50 beat Karyopharm Therapeutics' score of 0.22 indicating that Evoke Pharma is being referred to more favorably in the media.
Evoke Pharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Summary
Karyopharm Therapeutics beats Evoke Pharma on 9 of the 16 factors compared between the two stocks.
Get Evoke Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evoke Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:EVOK) was last updated on 7/16/2025 by MarketBeat.com Staff
